Effectiveness of a psychosocial intervention for relapse prevention in patients with schizophrenia receiving risperidone via long-acting injection

Psychiatry Research

Volumn 175, Issue 3, 2010, Pages 195-199

  Lee, Sang Hyuk ^a   Choi, Tae Kyou ^a   Suh, ShinYoung ^a   Kim, Yong Woo ^a   Kim, Borah ^a   Lee, EunHee ^a   Yook, Ki Hwan ^a  

^a CHA University   (South Korea)

Author keywords

Combined therapy; Long term outcome; Medication compliance; Relapse rate

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; HALOPERIDOL; LONG ACTING DRUG; RISPERIDONE;

ADULT; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PSYCHOSOCIAL CARE; RELAPSE; REMISSION; SCHIZOPHRENIA;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY, GROUP; RECURRENCE; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS; YOUNG ADULT;

EID: 73449130028     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.06.043     Document Type: Article

References (17)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. (1994), APA, Washington, DC
2. Chouinard G., Ross-Chouinard A., Annable L., and Jones B. The extrapyramidal symptom rating scale. [Abstract]. Canadian Journal of Neurological Science 7 3 (1980) 233
3. Davis J.M. Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry 132 (1975) 1237-1245
4. Drake R.J., Dunn G., Tarrier N., Bentall R.P., Haddock G., and Lewis S.W. Insight as a predictor of the outcome of first-episode nonaffective psychosis in a prospective cohort study in England. Journal of Clinical Psychiatry 68 (2007) 81-86
5. Feldmann R., Hornung W.P., Prein B., Buchkremer G., and Arolt V. Timing of psychoeducational psychotherapeutic interventions in schizophrenic patients. European Archives of Psychiatry and Clinical Neuroscience 252 (2002) 115-119
6. Guy W. Clinical Global Impressions (1976), National Institute of Mental Health, Rockville, MD
7. Herz M.I., Lamberti J.S., Mintz J., Scott R., O'Dell S.P., McCartan L., and Nix G. A program for relapse prevention in schizophrenia: a controlled study. Archives of General Psychiatry 57 (2000) 277-283
8. Hogarty G.E., Schooler N.R., Ulrich R., Mussare F., Ferro P., and Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Archives of General Psychiatry 36 (1979) 1283-1294
9. Kane J.M. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Journal of Clinical Psychiatry 64 (2003) 34-40
10. Kane J.M. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. Journal of Clinical Psychiatry 67 (2006) 9-14
11. Kane J.M., Eerdekens M., Lindenmayer J.P., Keith S.J., Lesem M., and Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry 160 (2003) 1125-1132
12. Kay S.R., Fiszbein A., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13 (1987) 261-276
13. Keith S.J., Kane J.M., Turner M., Conley R.R., and Nasrallah H.A. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. Journal of Clinical Psychiatry 65 (2004) 120-131
14. Lamberti J.S. Seven keys to relapse prevention in schizophrenia. Journal of Psychiatric Practice 7 4 (2001) 253-259
15. Lasser R.A., Bossie C.A., Gharabawi G.M., and Baldessarini R.J. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. International Journal of Neuropsychopharmacology 8 (2005) 427-438
16. Lasser R.A., Bossie C.A., Gharabawi G.M., and Kane J.M. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophrenia Research 77 (2005) 215-227
17. Zygmunt A. Interventions to improve medication adherence in schizophrenia. American Journal of Psychiatry 159 (2002) 1653-1664